Clinical Report: Indirect Comparison Analysis of Risankizumab and Icotrokinra
Overview
This study provides an indirect comparison of the clinical efficacy of risankizumab (RZB) and icotrokinra (ICO) in adults with moderate-to-severe plaque psoriasis.
Background
Risankizumab and icotrokinra are both approved treatments for moderate-to-severe psoriasis. This study employs a matching-adjusted indirect comparison to evaluate their effectiveness.
Data Highlights
No numerical data provided in the source material.
Key Findings
A higher proportion of patients treated with RZB achieved PASI 75, PASI 90, and PASI 100 compared to ICO.
Patients receiving RZB showed greater improvement in Investigator’s Global Assessment (IGA) scores than those on ICO.
Significant differences in efficacy were observed as early as week 4 or 8 and continued through week 52.
The study utilized a matching-adjusted indirect comparison method to reduce bias in treatment effect estimates.
Clinical Implications
The findings of this indirect comparison may inform treatment options for patients with moderate-to-severe psoriasis.
Conclusion
The indirect comparison provides insights into the efficacy of risankizumab and icotrokinra in treating moderate-to-severe plaque psoriasis.
by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober
